Therapeutic trials in hand osteoarthritis: A critical review  by Mejjad, O. & Maheu, E.
Osteoarthritis and Cartilage (2000) 8, Supplement A, $57-$63 
© 2000 OsteoArthritis Research Society International 
t ® doi:l 0.1053/joca.2000.0339, available online at http://www.idealibrary.com on | It I~ 
1063-4584/00/0AOS57+07 $35.00/0 
Osteoarthritis 
and Cartilage 
Journal of the OsteoArthritis Research Society International 
Therapeutic trials in hand osteoarthritis: a critical review 
O. Mejjad* and E. Maheul- 
*Department of Rheumatology, Centre Hospitalo-Universitaire de Rouen, France 
tDepartment of Rheumatology B, Cochin Hospital, 75014 Paris, France 
Summary 
Objective: To perform a critical review of the published therapeutic trials conducted in hand osteoarthritis (OA). 
Method: A Medline research was performed to select the clinical trials in hand OA published since 1994. 
Results: Twenty-five published studies were identified by this research, of which 10 were reported in abstract or short report forms. The trials 
were classified according to the study drug, and their methods and results examined. The critical analysis focuses on the design, the 
inclusion and efficacy criteria and the methodological imitations in all of these studies. 
Conclusion: Methodological restrictions of the studies are elucidated, such as the need for a consensus on diagnosis of hand OA, the need 
of valid, reliable and sensitive to change clinical assessment tools and validated radiological assessment methods in order to conduct trials 
in the future. © 2000 OsteoArthritis Research Society International 
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Introduction 
The hand is commonly affected by osteoarthritis (OA). 
Several studies have been conducted on epidemiology, 
genetics, clinical and radiological presentations of hand 
OA. Conversely, we found only 25 therapeutic studies in 
hand OA. In this review, we report the principal character- 
istics of the 25 studies published, and perform a critical 
analysis of the methodologies used. 
A previous review of the clinical trials conducted in hand 
OA was published in 1995.1 The present review analyses 
trials published since 1994 and those not reviewed in the 
above-cited paper. 
Summary and results of the trials 
ORAL NON-STEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS) 
(TABLE I) 
TWO studies of oral NSAIDs have been published. Seller 2 
included 41 patients with proximal interphalangeal joint 
(PIP) and distal interphalangeal joint (DIP) OA in a prospec- 
tive, randomized, double-blind study of a 4-week treatment 
period and 4-weeks of follow-up. Patients were to have at 
least three painful joints and at least one acute inflamed 
Heberden node. Diagnosis of OA was ascertained by X-ray 
examination. The results showed that meclofenamate at 
300 mg daily was more effective than placebo in improving 
pain measured on a scale ranging from 0=no pain to 
3=severe pain, the number of painful joints and the number 
of inflamed nodes. Grip strength did not improve. 
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In a prospective, randomized, double-blind trial con- 
ducted by Dreiser et aL, 3 60 patients with X-ray docu- 
mented OA of PIP, DIP and the first carpometacarpal 
(CMC1) joints were included. The sample size was calcu- 
lated prior to study initiation. The study consisted of a 
14-day treatment period and a 14-day follow-up. Patients 
needed to fulfill the following inclusion criteria: recent 
painful joint(s) of less than 15 days duration and pain on 
visual analog scale (VAS) of 40 mm or higher. The results 
showed that 1600 mg ibuprofen daily were more effective 
than placebo in improving spontaneous pain, pain on 
mobilization and on pressure, VAS score, and Dreiser's 
functional index for hand OA (FIHOA). 
In these two studies, diagnosis criteria and disease 
activity were defined, but no primary criterion was speci- 
fied. The pre-study calculation of the required sample size 
was performed only in Dreiser's study. 3 
OTHER TOPICAL NSAIDS (TABLE I) 
Seven studies of topical NSAIDs have been published, 
of which four were in abstract form. 
A prospective, randomized, comparative, double-blind 
trial of a 3-week treatment period and 3-weeks of follow-up, 
reported by Talke, 4 was performed in 60 patients with PIP 
and DIP OA. All of the patients had 'activated' Heberden's 
and Bouchard's arthritis. The results showed that topical 
etofenamate was as effective as oral indomethacin 150 mg 
daily, in improving pain at rest, pain on movement and on 
pressure using a VAS (P<0.05; P<0.001; P<0.01 respect- 
ively), joint circumference (P<0.001), range of motion 
(P<0.001), and grip strength using a Mannerfeld's intrinsic 
meter (P<0.05). 
In another study, Guillaume s compared 5% ibuprofen gel 
with the gel vehicle (placebo) in a prospective, randomized, 
double-blind trial of a 14-day treatment period and 14 days 
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Table I 
Design characteristics of therapeutic trials of oral or topical nonsteroidal anti-inflammatory drugs (NSAIDs) 
and of other topical drugs in hand OA 
Author(s) and references Drug/control Design Patients Inclusion criteria Results 
Oral NSAIDs 
Seller 2 Meclofenamate/ P DB R 41 PIP-DIP OA Meclofenamate> 
placebo placebo 
Dreiser et al. 3 1600 mg P DB R 60 PIP-DIP-CMC10A Ibuprofen>placebo 
Ibuprofen/placebo Flare <15 days 
VAS >_40 mm 
Topical NSAIDs 
Talke 4 Etofenamate P DB R 60 PIP-DIP OA Etofenamate=oral 
gel/1500 mg oral indomethacin 
indomethacin 
Guillaume s Ibuprofen gel/ P DB R 64 PIP-DIP-CMC10A Ibuprofen>placebo 
placebo Flare <15 days 
Augy 6 Ketoprofen gel/ P DB R 60 PIP-DIP-CMC10A Ibuprofen>placebo 
placebo Flare < 15 days 
Bourgeois and Dreiser ~ Niflumic acid P DB R 202 PIP-DIP-CMC10A Niflumic acid>placebo 
gel/placebo Flare <20 days 
VAS >_40 mm 
Gibeault and Wulwik 8 Niflumic acid P R 60 CMC10A Niflumic 
gel/dexamethasone Flare <20 days acid=dexamethasone 
VAS >_40 mm 
Dougados and Nguyen 9 Niflumic acid P DB R 186 PIP-DIP OA Niflumic acid=placebo 
gel/placebo 
Thiesce and Dougados 1° Diclofenac gel/ P DB R CO 20 DIP OA Diclfenac=placebo 
placebo 
Other topical drugs 
Vuillemin" Idrocilamide P DB R 96 PIP-DIP-CMC10A Idrocilamide>placebo 
gel/placebo 
McCarthy and McCarty ~2 0.075% capsaicin P DB R 14 Digital OA, without precision 0.075% capsaicin 
gel/placebo gel>placebo 
Schnitzer et al. 13 0.025% capsaicin P DB R 59 Hand OA, without precision 0.025% capsaicin 
gel/placebo gel>placebo 
Chouchane et aL TM Dexamethasone P DB R 90 PIP-DIP-CMC10A Dexamethasone> 
gel/vehicle/placebo Recent flare vehicle or placebo 
P=prospective; DB=double-blind; R=randomized; CO=cross-over; PIP=proximal interphalangeal; DIP=distal interphalangeal; CMCI= 
first carpometacarpal; OA=osteoarthritis. 
of follow-up. Sixty-four patients with OA of one to three finger 
joints were included. Except for pain at rest, ibuprofen gel 
was more effective (P<0.01) than the vehicle in improving 
spontaneous pain measured on a VAS, pain on mobilization 
and on pressure, Dreiser's functional index for hand OA, 
swelling, and global physician and patient assessment. 
In a prospective, randomized, double-blind trial of a 
14-day treatment period and 14-days of follow-up, Augy 
and Poiraud ~ enrolled 60 patients with X-ray documented 
OA in the PIP, DIP or CMC1 joints. Patient enrollment 
criteria included a flare of less than 2 weeks duration, 
involving one to three finger joints. The results showed that 
a 2.5% ketoprofen gel was more effective (P<0.05) than 
placebo on pain measured by VAS and Lickert scale, pain 
on pressure, pain on mobilization, joint swelling, and func- 
tional impairment measured on a verbal scale rating from 
0=none to 3=severe. 
Bourgeois and Dreiser ~ enrolled 202 patients with pain- 
ful PIP, DIP or CMC10A in a prospective, randomized, 
double-blind trial of a 14-day treatment period with a 14-day 
follow-up. The results showed that a 2.5% niflumic acid gel 
was more effective (P=0.02) than the gel vehicle (placebo) 
in improving spontaneous pain measured by VAS, global 
physician and patient assessments, pain at rest and on 
pressure, and the FIHOA. 
A prospective, randomized trial was performed by 
Gibeault and Wulwik. 8 Sixty patients with a flare of less 
than 20 days duration, pain on VAS of 40 mm or higher, and 
X-ray evidence of PIP, DIP or CMC10A were treated for 
14 days with 14 days of follow-up. The results showed that 
a 2.5% niflumic acid gel was as effective as a 0.5% 
dexamethasone gel in improving spontaneous pain, pain 
on pressure and on mobilization, range of motion and 
global patient assessment. 
Dougados and Nguyen 9 compared the" efficacy of a 
niflumic acid gel with the gel vehicle (placebo) in a prospec- 
tive, randomized, double-blind trial of 7-day treatment 
period with 7-day follow-up in 186 patients with painful 
Heberden's or Bouchard's nodes. The results showed that 
spontaneous pain, pain on mobilization and on pressure 
measured by the VAS improved in both groups but with no 
difference between the groups. 
In a prospective, randomized, cross-over trial of seven- 
day  treatment period with a seven-day follow-up duration 
performed by Thiesce and Dougados, 1° 20 patients with 
painful Heberden nodes were enrolled. The results showed 
that diclofenac gel was not superior to the gel vehicle 
(placebo) in improving pain, function (index not specified) 
or global assessment. 
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Table II 
Design characteristics of  therapeutic trials of  symptomatic slow-acting drugs on OA, of hydroxychloroquine 
and of  miscellaneous treatments in hand OA 
Author(s) and references Drug/control Design Patients Inclusion criteria Results 
Symptomatic slow acting drugs in OA 
Pastinen et al. 15 Periarticular P DB R 29 PIP-DIP-CMC10A GAG-PS>placebo 
GAG-PS/placebo 
Jonsson et aL 1~ Intramuscular O 12 Digital OA, without precision Pentosan-ps>placebo 
pentosan-ps/placebo 
Verbruggen et al. ~7 Oral chondroitine P DB R 119 PIP-DIP-MCP OA Chondroitin 
sulfate/placebo sulfate>placebo 
Wang et aL TM Oral chondroitine P DB 34 PIP-DIP OA Chondroitin 
sulfate/placebo sulfate>placebo 
Rovetta and Monteforte ~9 GAGs/placebo P DB R 24 PIP-DIP-CMC1 erosive OA GAGs>placebo 
Verbruggen et al. 2° Xylanpolysulfate per P DB R 50 Digital OA Xylanpolysulfate> 
os/placebo placebo 
Hydroxychloroquine (HCQ) 
Robertson et aL 21 HCQ Retrospective 7 PIP-DIP-MCP-CMC10A HCQ effective 
Bryant et al. 22 HCQ Retrospective 8 PIP-DIP erosive OA HCQ effective 
Punzi et aL 23 HCQ/NSAIDs or P R 15 PIP-DIP erosive OA HCQ effective 
analgesics 
Miscellaneous treatments 
Flynn eta/. 24 Cobalamin+folate/ P DB R CO 26 PIP-DIP-CMC10A Cobalamin+folate> 
folate/placebo folate or placebo 
Garfinkel eta/. 2s Yoga/usual treatment P R 25 PIP-DIP OA Yoga>usual treatment 
Graber et al. 2G Berthollet/ibuprofen P R 116 Digital OA Berthollet>ibuprofen 
gel gel 
Dreiser_>5 
P=prospective; DB=double-blind; R= randomized; CO=cross-over; O=open; PIP=proximal interphalangeal; DIP=distal 
interphalangeal; CMC1 =first carpometacarpal; MCP=metacarpophalangeal; OA=osteoarthritis. 
In all of these seven studies, diagnosis criteria and 
disease activity were never well-defined. A primary criterion 
was specified only in the trial performed by Dougados and 
Nguyen. 9 There was no pre-study calculation of the sample 
size performed. 
OTHER TOPICAL DRUGS (TABLE I) 
Idrocilamide gel, an agent with muscle relaxant 
properties, was compared to the gel vehicle (placebo) in 
a prospective, randomized, double-blind trial of a 7-day 
treatment period with a 7-day follow-up performed by 
Vuillemin. 11 Ninety-six patients with a flare of PIP, DIP and 
CMC10A were enrolled. Idrocilamide gel was found to 
be more effective than placebo on pain assessed by a 
self-evaluated score, and on improvement in mobility. 
Capsaicin was evaluated in two trials. The first, a 
prospective, randomized, double-blind trial was performed 
by McCarthy and McCarty 12 in 14 patients with painful PIP, 
DIP and CMC10A for 4 weeks with a 4-week follow-up. 
Diagnosis of OA was based on 'classical findings on 
examination' which include evidence of OA nodes. The 
0.075% capsaicin gel was found to be more effective than 
the gel vehicle (placebo) in improving joint tenderness as 
measured by a standardized dolorimeter (P<O.02), and 
pain assessed by VAS (P<0.02). No differences were found 
in changes of grip strength, morning stiffness or joint 
swelling. In this study, a group of RA patients was also 
included. Results were given on 267 joints in 14 patients. 
The second trial was a prospective, randomized, double- 
blind study of 9-week treatment duration period with 
9-weeks of follow-up, performed by Schnitzer et aL ~3 
Fi•-nine patients with painful hand OA were enrolled. 
Diagnosis of OA was based on physical, biological and 
X-ray examinations. The results showed that 0.025% 
capsaicin cream was superior to placebo in improving joint 
tenderness (P=0.01), pain on a VAS (P=0.01), joint swell- 
ing, function using a verbal scale ranging from 0 to 3, and 
grip strength. 
Chouchane et aL TM performed a prospective, random- 
ized, double-blind trial of a 7-day treatment period with 
7 days of follow-up in 90 patients with a flare of PIP, DIP 
or CMC10A. The results showed that dexamethasone 
gel was more effective than both the salicylate vehicle 
(P<0.01) and placebo (P<0.05) in improving pain on VAS 
(spontaneous pain, pain at night, pain on pressure and on 
mobilization), in improving function using a verbal scale 
ranging from 1 to 3 and patient global assessment. 
In these four studies, neither the disease activity, nor 
the primary criterion were well-defined. There was no 
pre-study calculation of the sample size performed. 
Diagnosis criteria were defined only in the Schnitzer's 
study.13 
SYMPTOMATIC SLOW-ACTING DRUGS IN OA (SyoSADOA) AND 
DISEASE MODIFYING DRUGS IN OA (DMOADS) (TABLE II) 
Six studies including four abstracts or short reports of 
Sy-SADOA or DMOAD in hand OA were identified. 
Twenty-nine patients with painful PIP, DIP and CMC10A 
were included in a prospective, randomized, double- 
blind trial performed by Pastinen et  al. ~s Their OA was 
diagnosed by both clinical and radiological findings. Nine 
periarticular injections of glycosaminoglycan polysulfate 
(GAG-PS) given over 13 weeks were found to be more 
effective than placebo in improving morning stiffness 
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(P=0.01), grip and pinch strength as measured by a 
dynamometer (P<O.01), function using a verbal scale 
ranging from 0 to 3 (P<0.01), but not pain on VAS. The 
end-point assessment took place 26 weeks after the 
injections. 
Four weekly intramuscular injections of pentosan 
polysulfate (3 mg/kg) were assessed in an open study by 
Jonsson et aL ~6 in 12 patients with 'severe symptomatic 
hand OA'. Pentosan polysulfate was found to b,e effective in 
relieving pain, improving grip strength, improving scores of 
the 'ISHOA hand disability scale' (statistics not provided), 
but not on OA activity assessed by scintiscan performed 
10 days after drug administration. The criteria used for the 
diagnosis of OA were not specified. 
Oral chondroitin sulfate was more effective than placebo 
in two studies. The first was a prospective, randomized, 
double-blind study performed by Verbruggen etal .  ~7 on 119 
patients with PIP, DIP and CMC10A diagnosed using 
X-ray features. The structural effect of chondroitin sulfate at 
1200 mg daily compared with placebo was assessed by a 
radiological scoring during a 3-year follow-up. The results 
showed that a comparable number of patients in both 
treated and placebo groups developed OA in non- 
previously involved joints. However, a significantly lower 
incidence with regard to the number of patients showing 
new erosive OA of the finger joints was observed in the 
treated group. 
The second trial performed by Wang et al. ~ in 34 
patients with painful PIP and DIP OA was prospective, 
randomized, and double-blind. Oral chondroitin sulfate at 
1200 mg daily was compared with placebo. The results 
showed that chondroitin sulfate was more effective than 
placebo on pain assessed by VAS (P<0.05), grip strength 
(P<0.05), but not on circumference of joints. Twenty per 
cent of the previously unaffected joints in the treated group 
developed OA, vs 15% in the placebo group during a 
two-year follow-up with a radiological assessment. There 
was no significant difference between the groups in the 
development of OA in joints previously unaffected. 
A prospective, randomized, double-blind trial performed 
by Rovetta and Monteforte 19 compared the efficacy of 
galactosaminoglycuroglycan sulfate (GAGs) to placebo in 
24 patients with 'frank' painful erosive PIP, DIP or CMC1 
OA. Diagnosis of erosive OA was based on X-ray findings. 
The results showed that oral GAG was more effective than 
placebo on measures of pain, and joint erosions, but not on 
joint scintiscans performed 2 years apart in parallel to the 
clinical and radiological assessments. It must be noticed 
that there were fewer joint erosions in the treated group 
compared to the placebo group at baseline. 
Verbruggen et al. 2° performed a prospective, random- 
ized,double-blind study in 50 patients with 'inflammatory' 
hand OA. A polysaccharide, xylanpolysulfate (XPS), given 
orally at 20 mg/kg twice a week, was more effective than 
placebo in relieving pain, morning stiffness, pain at night, 
function assessed by the 'Ghent' functional index during a 
24-week follow-up. Grip strength and concomitant use of 
analgesics did not show any improvement. 
Diagnosis criteria were defined only in the trials 
performed by Verbruggen et al. ~z and Rovetta and 
Monteforte. ~9 Disease activity was specified only in 
Rovetta's study. ~9 The primary criterion was specified 
in Jonsson et a/.'s 16 and Verbruggen's 17 studies. The 
pre-study calculation of the required sample size was never 
performed. 
HYDROXYCHLOROQUINE (TABLE II) 
Three studies of hydroxychloroquine (HCQ) in erosive 
hand OA, including one abstract and one letter, are 
reviewed. 
HCQ at a dose of 200-400 mg daily was effective in 
seven patients with evidence of erosive PIP, DIP or CMC1 
OA on X-ray in an open retrospective study reported by 
Robertson et al. 21 Two patients had positive antinuclear 
antibodies (ANA) at baseline. 
Bryant et al. 22 reported the results of an open, retrospec- 
tive study. All patients had 'inflammatory arthritis' of PIP 
and DIP joints, with radiographic changes consistent with 
OA. The results showed that, among eight patients with 
erosive OA, HCQ at a 400 mg daily dosage resulted in an 
improvement of synovitis, morning stiffness and global 
assessment in six patients, Three of them had positive ANA 
at baseline. 
Punzi et al. 23 performed a prospective, randomized, 
double-blind, and placebo-controlled trial, in 15 patients 
with 'inflammatory arthritis' of PIP and DIP joints, with 
radiological changes consistent with OA. Efficacy was 
assessed by clinical (Ritchie Index) and biological (sedi- 
mentation rate, interleukin-2 receptor level) tests with a 
12-month follow-up. The results showed that HCQ was 
more effective than placebo on clinical and biological 
assessments. 
Diagnosis criteria were defined in each of these three 
studies. Disease activity was not well-defined in Punzi's 23 
trial. The primary criterion was never specified, nor the 
pre-study calculation of the sample size performed. 
MISCELLANEOUS TREATMENTS (TABLE II) 
In a prospective, randomized, double blind study 
performed by Flynn et af. 24 in 26 patients with PIP, DIP and 
CMC10A (ACR criteria, X-ray changes), 20pg oral 
cobalamin combined with 6400 ~.tg of folate was compared 
with folate alone or placebo. Severity of OA was designated 
clinically, as 'active' or 'inactive'. The results showed that 
the combination of vitamin B12 and folate was more 
effective than folate alone or placebo, in improving pain, 
morning stiffness, activity, psychological parameters, grip 
strength, and number of tender and painful PIP or DIP 
joints. 
A yoga program was evaluated in 25 patients with painful 
PIP, DIP or CMC10A (ACR criteria) in a prospective 
randomized designed trial performed by Garfinkel et aL 25 
The results showed that the yoga program combined with 
standard treatment was more effective than the usual 
treatment alone in improving pain, grip strength, motion, 
joint circumference, tenderness and hand function 
assessed by the Stanford hand assessment questionnaire. 
In a prospective randomized trial performed at the 
Aix-les-Bains spa, a local treatment called berthol let  was 
compared to ibuprofen gel. The trial was performed by 
Graber et al. 26 in 116 patients with painful PIP, DIP and 
CMCl OA (ACR criteria) and a Dreiser's functional index 
score >5. The results showed that berthol let  treatment was 
more effective than ibuprofen gel in improving pain, grip 
strength, joint circumference and global assessment at a 
6-month follow-up. 
Diagnosis criteria were defined in each of these three 
studies. Disease activity was not well-defined in Garfinkel's 
trial. 25 A primary criterion was specified only by Garfinkel.25 
No pre-study calculation of the sample size was performed. 
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Table III 
Efficacy criteria and methodo/ogica/ /imitations in therapeutic trials of ora/ or topica/ nonsteroida/ antiinf/ammatory drugs (NSA/Ds) 
and of other topica/ drugs in hand OA 
Author(s) ref Efficacy criteria Methodological limitations 
Oral NSAIDs 
Seller 2 Painful joint count; pain score (from 0 to 3); inflammatory Heberden D+. A+. P-. S-. 
nodes count; grip strength 
Patient and physician global assessment; VAS pain; pain on D+. A+. S+. 
mobilization, on palpation; functional index; swelling; acetaminophen No single main criterion 
use 
Dreiser et al. 3 
Topical NSAIDs 
Talke 4 
Guillaume s
Augy and Poiraud 6 
Bourgeois and Dreiser 7 
Gibeault and Wulwik 8 
Dougados and Nguyen 9 
Thiesce and Dougados 1° 
Other topical drugs 
Vuillemin 1~ 
McCarthy and McCarty ~ 
Schnitzer et aL ~3 
Chouchane et al. TM 
Patient and physician global assessment; pain at rest; on mobilization 
(scored from 0 to 10); circumference; range of motion, grip strength 
VAS pain; pain on mobilization; on palpation; functional impairment; 
range of motion; pain at night; swelling; patient and physician global 
assessment 
VAS pain; range of motion; swelling; pain at night; compliance 
Patient and physician global assessment; VAS pain; pain at rest; on 
palpation; on mobilization; range of motion; functional index; 
acetaminophen use 
Patient and physician global assessment; VAS pain; pain on palpation; 
on mobilization; range of motion 
VAS for spontaneous pain; pain on mobilization; pain on pressure 
Global assessment; VAS pain; functional score 
Daily self-evaluation; pain; range of motion; global assessment 
VAS pain; functional index (HAQ); morning stiffness; grip strength; 
swelling; pain on palpation 
Joint tenderness; VAS pain; grip strength; swelling; functional index 
VAS pain; pain at night; on mobilization; on pressure; function score; 
swelling; global assessment 
D-. A-. P-. S-. 
D-. P-. S-. 
D-. A-.  P-. S-. 
D-. A-. S-. 
No single main criterion 
D-. A-.  S-. 
D-. A-.  P+. 
D-. A-.  P-. 
D-. A-.  S-. 
D-. A-.  P-. S-. 
Results on 267 joints in 14 patients 
D+. A-.  P-. S-. 
D-. A-. P-. S-. 
VAS=visual analog scale; HAQ=health assessment questionnaire. D=diagnostic criteria; A=disease activity criteria; P=primary 
criterion; S=pre-study calculation of the required sample size; + =defined or specified; -=not specified or not well defined. 
Critical analysis 
Among the 25 studies, 10 were reported in abstract or 
short report format, providing much less information than 
full papers. Seventeen studies were prospective, random- 
ized, double-blind trials; two used a cross-over design; two 
were retrospective; and three were open studies. Eighteen 
were placebo-controlled trials, three compared a topical 
NSAID with another drug, and four were controlled. For this 
review, we found no study assessing the efficacy of intra- 
articular corticosteroid injections, or the use of splints in 
hand OA, in particular for the thumb base. 
CRITERIA FOR THE DIAGNOSIS OF HAND OA (TABLES III AND IV) 
The criteria used for the diagnosis of OA were not 
specified in 12 of the reviewed trials. The clinical and/or 
radiological criteria for the diagnosis of OA were usually 
poorly defined or not specified. The ACR criteria for the 
classification and reporting of hand OA were used in only 
two studies. Patients with PIP, DIP and/or CMC10A were 
included in 10 trials. Nine trials included patients with 
PIP-DIP OA only, and one included patients presenting 
with CMC10A alone. The exact location of hand OA was 
not specified in five studies. As new trials are designed, the 
following questions regarding diagnosis of hand OA need to 
be addressed: should hand OA be defined similarly in trials 
assessing the symptomatic and structural effects of drugs? 
Should interphalangeal and CMC1 joints be combined in 
trials assessing symptomatic effects, or should they be 
studied separately? 
INCLUSION CRITERIA (TABLES III AND IV) 
Inclusion criteria of the reviewed trials typically state that 
'painful', or 'inflammatory', or a 'flare' of hand OA was 
required for selection. However, in 18 out of the 25 studies, 
inclusion criteria were not specified or well defined. Only 
two studies required a specified level of measures of 
symptoms such as a minimal VAS pain score or Dreiser's 
functional index value (one trial). With the exception of 
two studies, the symptom activity was not well defined 
(inflammatory nodes, swelling, pain) and flare onset was 
not well described. Similar comments can be made con- 
cerning the severity of OA which was usually not clearly 
specified or well defined. As new trials are designed, the 
following questions need to be addressed: How should the 
symptom activity and/or severity criteria be measured in 
hand OA trials? What minimal VAS pain level should 
be used for selection criteria? What should the minimal 
number of painful joints be at entry? What should the 
minimal value of the functional index score be? 
EFFICACY ASSESSMENT CRITERIA (TABLES III AND IV) 
More than 23 different efficacy criteria were used in the 
25 trials. There was a range of one to eight criteria per 
study. The VAS for pain assessment was used in 16 
studies. Other criteria often used were pain on mobilization, 
pain on pressure, pain at night, and morning stiffness. Grip 
strength measurements were also frequently used; how- 
ever, the procedures were neither standardized nor ident- 
ified. The functional indices also varied and were poorly 
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Table IV 
Efficacy criteria and metho/ogica/ /imitations in therapeutic trials of symptomatic s/ow-acting drugs on OA, of hydroxych/oroquine 
and of misce//aneous treatments in hand OA 
Author(s) ref Efficacy criteria Methodological limitations 
Jonsson et al. ~6 
Verbruggen et aL ~7 
Wang ~8 
Rovetta and Monteforte TM 
Verbruggen et al. 2° 
Hydroxychloroquine 
Robertson et aL 21 
Bryant eta/. 22 
Punzi et al. 23 
Miscellaneous treatments 
Flynn et aL 24 
Garfinkel eta/. 25 
Graber et al. 26 
Symptomatic slow acting drugs in OA 
Pastinen et aL is Global assessment; morning stiffness; grip strength; pinch strength; VAS pain 
during the tests 
99mTc-diphosphonate uptake VAS pain; grip strength; hand disability scale 
X-ray criterion: personal scoring; count of newly affected joints 
X-ray changes after a ~-year follow-up; VAS pain; grip strength; joint 
circumference 
Personal score=Ritchie index; number of central erosion; number of joints 
with a positive scintiscan; number of joint ankylosis 
VAS pain; morning stiffness; pain at night; function score; 'Ghent' functional 
index; grip strength; pain on palpation; analgesics use 
Global improvement; swelling 
Morning stiffness; synovitis; erosions; patient global assessment 
Ritchie index; erythrocyte sedimentation rate; soluble interleukin-2-receptor 
concentration 
Grip strength; painful joint count; morning stiffness; compliance; patient and 
physician global assessment 
Range of motion; grip strength; joint tenderness; circumference; VAS pain; 
function index (Stanford questionnaire) 
Dreiser's index; VAS pain; grip strength; swelling; physician global 
assessment 
D-. A-. P-. S-. 
D-. A-. P+. S-. 
D+. A-. P+. S-. 
D-. A-. P-. S-. 
D+. A+. P-. S-. 
D-. A-. P-. S-. 
D+. A+. P-. S-. 
D+. A+. P-. S-. 
D+. A-. P-. S-. 
D+. A+. P-. S-. 
D+. A-. P+. S-. 
D+. A+. P-. 
VAS=visual analog scale; D=diagnostic criteria; A=disease activity criteria; P=primary criterion; S=pre-study calculation of the 
required sample size; +=defined or specified; -=not specified or not well defined. 
defined. Dreiser's functional index (FIHOA) was used in 
three studies. The following indices were used once: 
'Ghent', health assessment questionnaire (HAQ), 
ISHOA(?), and the Stanford hand assessment question- 
naire. Most studies failed to specify the primary evaluation 
criterion. This raises the question: what primary criterion 
should be used in trials in hand OA? If a functional index is 
required, which one should be used? It is important to 
answer these questions in order to standardize clinical 
trials in hand OA and to determine a priori anticipated, 
clinically relevant differences between the treatments 
groups. Moreover, this is necessary to calculate sample 
sizes of trials. In the trials reviewed, the number of patients 
ranged from seven to 202. The required sample size was 
determined in advance in only one trial. 
ASSESSING STRUCTURE-MODIFYING DRUGS 
Among the six studies reviewed, four were reported as 
abstracts or short papers. Only three of them presented 
results on long-term follow-up (more than 2 years), looking 
at changes in X-rays to assess structural effect. The 
minimum duration of trials measuring structural effects of 
drugs in hand OA is not currently known. Is X-ray assess- 
ment the best method to measure efficacy? Which radio- 
logical scoring method should be used to assess OA 
progression? These issues need to be addressed as future 
trials in the therapeutic treatment of hand OA are planned 
and conducted. 
To summarize, the review of published data on hand OA 
raises more questions than it answers with regard to the 
evaluation of therapeutic agents. Despite the numerous 
methodological limitations reported above, most studies 
concluded that the tested drug was effective in improving 
hand OA symptoms. This review raises several issues, and 
the authors make the following recommendations: (1) A 
consensus needs to be reached on diagnosing hand OA, 
the definitions of the disease, its severity and symptom 
activity, allowing for standardized selection of patients; (2) 
primary and secondary evaluation criteria with appropriate, 
validated, reliable and sensitive tools need to be selected; 
(3) the now widely accepted guidelines for the conduct of 
clinical trials in OAF  should be adapted for further specific 
studies in hand OA. 
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